Tokyo Tape
Sign in
← Qol Holdings

Quarterly report · Q2

3034.TEDINET S100SA13
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥170.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥82.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥4.0bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥10.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.2bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥2.4bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥107.4bnat 2023-09-30Cons.Assets
Total assets¥101.9bnat 2023-03-31Cons.Assets
Total assets¥91.0bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥57.1bnat 2023-09-30Cons.Liabilities
Total liabilities¥53.0bnat 2023-03-31Cons.Liabilities
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets
Net assets / equity¥48.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥45.9bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥17.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥18.8bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥14.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥16.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥11.7bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥4.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥23.582023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥152.962022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.112022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.922022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio47.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio50.4%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥231m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥231m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥7.6bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥167m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥658m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥231m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥181m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥181m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.7bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥75.6bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥75.6bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥58m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥7.0bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥6.9bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥123m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥645m
—segment totalrevenue2022-04-01 → 2022-09-30¥82.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥82.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥181m
—segment totalsegment profit2022-04-01 → 2022-09-30¥5.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Cash and cash equivalentsPrior2YearInstant16516000000JPY
Cash and cash equivalentsPrior1YearInstant18596000000JPY
Cash and cash equivalentsPrior1QuarterInstant14323000000JPY
Cash and cash equivalentsCurrentQuarterInstant17253000000JPY
Payroll and allowances sgaPrior1YTDDuration1468000000JPY
Payroll and allowances sgaCurrentYTDDuration1521000000JPY
Provision for bonuses personnel expensesPrior1YTDDuration148000000JPY
Provision for bonuses personnel expensesCurrentYTDDuration176000000JPY
Retirement benefit expenses sgaPrior1YTDDuration32000000JPY
Retirement benefit expenses sgaCurrentYTDDuration32000000JPY
Amortization of goodwill elPrior1YTDDuration1583000000JPY
Amortization of goodwill elCurrentYTDDuration1675000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember75557000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember6901000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember82459000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration82459000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember58000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember123000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember181000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-181000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember75615000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember7025000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember82641000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-181000000JPY
Net salesPrior1YTDDuration82459000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember5056000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember645000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember5702000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-1680000000JPY
Operating incomePrior1YTDDuration4022000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember80966000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember7573000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember88540000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration88540000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember63000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember167000000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember231000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-231000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember81030000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember7741000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember88771000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-231000000JPY
Net salesCurrentYTDDuration88540000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember4714000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember658000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember5372000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass